Telix Pharmaceuticals Ltd. has announced the cessation of Harry Kevin McCann as a director, effective from May 21, 2025. According to the final director's interest notice, McCann holds no securities as a registered holder. However, through Monjoy Pty Limited and Cottesloe Pty Limited, McCann has indirect interests in 130,000 and 990,000 fully paid ordinary shares, respectively. There are no disclosed interests in contracts related to commercial paper.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.